GuiZhou SanLi Pharmaceutical Co.,Ltd

Shanghai Stock Exchange 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd EBITDA for the year ending December 31, 2023: USD 52.00 M

GuiZhou SanLi Pharmaceutical Co.,Ltd EBITDA is USD 52.00 M for the year ending December 31, 2023, a 47.07% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

GuiZhou SanLi Pharmaceutical Co.,Ltd EBITDA for the year ending December 31, 2022 was USD 35.36 M, a 17.27% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd EBITDA for the year ending December 31, 2021 was USD 30.15 M, a 74.20% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd EBITDA for the year ending December 31, 2020 was USD 17.31 M, a -24.54% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd EBITDA for the year ending December 31, 2019 was USD 22.94 M, a 14.29% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Shanghai Stock Exchange: 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd

CEO	Mr. Hai Zhang
IPO Date	April 28, 2020
Location	China
Headquarters	Xiayun Industrial Park
Employees	2,282
Sector	Health Care
Industries Pharmaceuticals

Description

GuiZhou SanLi Pharmaceutical Co.,LTD. engages in the research and development, production, and marketing of pharmaceutical products. It offers pediatric medication, respiratory system medication, cardiovascular and cerebrovascular drugs, digestive medicine, trauma injury medication, rehabilitation medicine, and ophthalmic medicine. The company was founded in 1995 and is based in Guiyang, China.

Key trends

Past 5 years